Vigintillion Capital is a professional private equity firm approved
by the Asset Management Association of China (AMAC)（Registration No. P1061033).
Vigintillion Capital focuses on private equity investment in life sciences and healthcare. We mainly invest in promising growth and maturity stage companies in China and abroad.
We are founded by industry veterans and supported by several well respected financial and industrial conglomerates. While creating value for investors, we adhere to the principle that financial investment should be performed with industrial aspiration in mind. In all of our proposed or invested projects, we have proposed or transmitted tailor-made strategic values to target companies to support their long-term development.
In April 2016, China Resources Medical injected its main medical assets into Phoenix Healthcare Group (1515.HK), a listed company in Hong Kong. After the reorganization, Phoenix Healthcare was renamed China Resources Phoenix Healthcare Group, and China Resources Medical became the largest shareholder. The reorganized China Resources Phoenix Healthcare operates 107 hospitals with 11,780 beds in mainland China, making it the largest medical service group in Asia. In the same year, under the leadership of China Resources Medical, China Resources Phoenix Healthcare invested in Vigintillion Capital and both parties signed a Comprehensive Strategic Cooperation Agreement.
China Cinda Asset Management Co., Ltd. is a state-owned non-banking financial institution approved by the State Council and owned by the Ministry of Finance. On December 12th, 2013, China Cinda was listed on the main board of the Stock Exchange of Hong Kong. By the end of 2017, China Cinda's total asset amounted to 1386.9 billion RMB. In the 2007 issue of Fortune China 500, Cinda ranked 78th in operating revenue and 31st in profit.
Yuexiu Group was established in Hong Kong in 1985. After 35 years of reform and development, the Group has formed a “4+X” modern industrial system with core industries such as finance, real estate, transportation infrastructure, agriculture and food and emerging industries such as healthcare and high-tech. By the end of 2019, the total assets reached RMB666.2bn, among which the total assets of the financial sector exceeded RMB310bn. The company owns two financial holding platform listed companies, Guangzhou Yuexiu Financial Holding (000987.SZ) and Hong Kong Yuexiu Financial Holding (01111.HK). Guangzhou Yuexiu Financial Holdings Group was established in 2012, which was a crucial strategic progress of Yuexiu Group’s financial core industry layout. In 2016, the company entered the capital market, and became the first local financial holdings listed platform in China. The company currently has financial business platforms such as Guangzhou Assets, Yuexiu Leasing, Yuexiu Industrial Fund, Yuexiu Financial Holding Capital, Yuexiu Guarantee, Guangzhou Futures, Yuexiu Fintech, etc., and is the second largest shareholder of Citic Securities. After 8 years of development, the total assets of the company has been nearly RMB120bn.
Chairman and Founding Partner
Mr. Kevin Guan has over 20 years of experience in capital market investment in China, U.S., Southeast Asia, and the Middle East. Prior to founding Vigintillion, Mr. Guan has served as Executive Director and person in charge of healthcare investment at Pacific Alliance Group (PAG) with an AUM of 30 billion USD. At Vigintillion, he is responsible for investment strategy,risk management, project development and overall operations of the fund. Mr. Guan holds an M.B.A. from Wharton Business School and an E.M.B.A. from PBC School of Finance at Tsinghua University. Chartered Financial Analyst (CFA), Certified Public Accountant (CPA), Vice Chairman of ASEAN Economic Cooperation Foundation China Affairs Department, Director of Tsinghua PBC Intelligent Finance Center, Member of China Youth Entrepreneurs Association.
Managing Director and Partner
Mr. Brook Wu has nearly 30 years of experience in the field of pharmaceutical and healthcare. He has served as a senior executive in Pfizer, MSD, Abbott, Takeda, Mundipharma, China Resources Double-Crane and other multinational or domestic enterprises.He has objective and profound knowledge, as well as unique views on the pharmaceutical industry. At Vigintillion, Mr. Wu is responsible for investment strategy, project development, investment execution and post-investment management. Mr. Wu holds a Bachelor of Pharmacy from China Pharmaceutical University and an M.B.A. from Marshall Business School at University of Southern California.and is the founder of China Pharmaceutical BD Alliance.
At Vigintillion, he is responsible for investment strategy, project development, investment execution and post-investment management.